NOVARTIS INDIA LTD.

Novartis India Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a Profit After Tax (PAT) of ₹322.1 million, an increase from ₹276.2 million in the same quarter last year. Total income for the quarter stood at ₹1,725.5 million. Expenses were reported at ₹693.8 million. The company also disclosed that it has a single operating segment, 'Pharmaceutical Business', and operates solely within India. There were no deviations or defaults on loans and debt securities, and related party transactions were not applicable for this filing. The results have been subjected to a limited review by the statutory auditors.

Novartis India Limited's Board of Directors convened on July 23, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The board also took on record the limited review report issued by the company's statutory auditors. The meeting commenced at 11:20 AM IST and concluded at 12:30 PM IST. The approved unaudited financial results and the limited review report are available on the company's website.

Axis Capital Ltd, acting as the Manager to the Open Offer for Novartis India Limited, has submitted a Post-Offer advertisement to BSE. This advertisement complies with Regulation 18(12) of the SEBI (SAST) Regulations. The open offer was made by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, along with persons acting in concert, for the acquisition of up to 64,19,608 equity shares, representing 26% of the voting share capital of Novartis India Limited. The advertisement was published on July 10, 2026, in Financial Express (English), Jansatta (Hindi), and Navshakti (Marathi).

Novartis India Ltd has announced that its Board of Directors will convene on July 23, 2026. The primary agenda for this meeting is to consider and approve the company's unaudited financial results for the quarter ended June 30, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Novartis India Limited has announced the closure of its trading window for designated persons and their relatives. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the company intimates its unaudited financial results for the quarter ended June 30, 2026, to the stock exchange. The decision aligns with SEBI regulations concerning insider trading.

Axis Capital Ltd, acting as the Manager to the Open Offer for Novartis India Limited, has submitted a disclosure regarding the number of equity shares tendered. As of June 24, 2026, no shares have been tendered into the Open Offer Escrow Demat Account. However, 182 equity shares have been tendered in physical form with the Registrar to the Open Offer. These figures represent 0.00% of the total Offer Size. The tendered shares are subject to validation and verification as per SEBI (SAST) Regulations and the Letter of Offer.

Axis Capital Ltd, acting as the Manager to the Open Offer for Novartis India Limited, has submitted a disclosure regarding the number of equity shares tendered. As of June 23, 2026, NIL equity shares have been tendered in the Open Offer Escrow Demat Account, representing 0% of the offer size. Additionally, 112 equity shares (0.00% of the offer size) have been tendered in physical form. These figures are subject to validation and verification. The Open Offer is being made by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners to acquire up to 26% of the voting share capital of Novartis India Limited.

Axis Capital Ltd, acting as the Manager to the Open Offer for Novartis India Limited, has submitted a disclosure regarding the number of equity shares tendered. As of June 22, 2026, only 10 equity shares have been tendered in physical form to the Registrar, representing 0.00% of the offer size. No shares have been tendered in the Open Offer Escrow Demat Account. The open offer is for the acquisition of up to 26% of the voting share capital by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, along with persons acting in concert. The tendered shares are subject to validation and verification.

Axis Capital Ltd, the Manager to the Open Offer for Novartis India Limited, has provided an update on the acquisition of up to 64,19,608 equity shares (26% of voting share capital) by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. As of June 19, 2026, only 10 equity shares have been tendered in physical form to the Registrar, while zero shares have been tendered in dematerialized form into the Open Offer Escrow Demat Account. The disclosure clarifies that these figures reflect shares received and are subject to validation. The final acceptance will be in accordance with SEBI regulations and the Letter of Offer.

Axis Capital Ltd, the Manager to the Open Offer for Novartis India Limited, has disclosed that as of June 18, 2026, no equity shares have been tendered into the Open Offer Escrow Demat Account. Additionally, only 10 equity shares have been tendered in physical form. This disclosure pertains to the Open Offer by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners to acquire up to 26% of the Target Company's voting share capital. The tendered shares are subject to validation and verification.